Spotlight

Conversations

Proven, Complementary Weight Loss Mechanism: CB1 Inhibition

The CB1 inhibition mechanism has shown clinically validated and meaningful weight loss. Nimacimab offers a differentiated, peripherally targeted approach with unique potential to complement GLP1/incretin therapeutics.

Released July 9, 2025

Heterogeneous Needs Not Fulfilled by Approved Incretin Drugs Alone

Tu Diep, Skye Bioscience's COO, discusses historical views toward obesity, its emerging acceptance as a disease, and unmet treatment needs left by GLP1/incretins.

Released July 6, 2025

Skye + Obesity Specialists Discuss Non-incretin Therapeutics

Led by Evercore equity analysts, Skye executives join notable obesity physicians to discuss the CB1 pathway, Skye's peripheral CB1 inhibitor, and the broader non-incretin toolkit supporting obesity care beyond the limits of GLP-1s.

Released June 21, 2025

Chief Operating Officer: An Outlook on Work & Life

Tu Diep, Skye Bioscience's COO, discusses value and his perspective on making a positive contribution.

Released April 5, 2025

Expert Panel with Skye CEO + Obesity Specialist

South by Southwest panel with CEO Punit Dhillon and Clinical Advisor Beverly Tchang, MD, discusses need for sustainable weight loss, emerging advancements, combination therapies, and possibilities for CB1 inhibition.

Released March 10, 2025

SXSW 2025 Pre-panel Chat Covers Broad Obesity-related Topics

Skye CEO Punit Dhillon and Clinical Advisory Board Member Dr. Beverly Tchang, MD, chat about SXSW 2025 and weight loss ahead of their panel, “Weighing in on Weight Loss.”

Released March 9, 2025

COO Reflects on the Challenges and Path of His Journey

Tu Diep, Skye Bioscience's COO, discusses his lifelong passion, interest and work leading into the drug development journey of lead asset nimacimab.

Released March 5, 2025